How the once-dominant cancer company has overhauled its strategy for long-term growth

Last year matched 2018’s record for FDA product approvals accompanied by pharmacogenomic tests

Plus Celltrion gains rights to T cell engager from Abpro, and updates from Moat, Day One, Secura and more

In the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy test, growing the number of genetic biomarkers indicated for

Blueprint receives $775M up front, diagnostic capabilities via licensing deal for RET inhibitor pralsetinib

New payment models are aiming to break the logjam on reimbursement for cancer diagnostics

Thrive launches with Third Rock-led $110M series A to develop a liquid biopsy test for the early detection of cancer that could challenge Grail, Guardant

How ctDNA could move into applications beyond patient stratification